Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study

Pharmacotherapy

Volumn 36, Issue 5, 2016, Pages 463-471

  Hammond, Drayton A ^a,b   Smith, Melanie N ^c   Painter, Jacob T ^a   Meena, Nikhil K ^d   Lusardi, Katherine ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF FLORIDA HEALTH JACKSONVILLE   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Acute kidney injury; Cefepime; Critically ill; Nephrotoxicity; Piperacillin tazobactam; Vancomycin; lactam

Indexed keywords

CEFEPIME; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE DURATION; DRUG SAFETY; FEMALE; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SEPTIC SHOCK; TREATMENT OUTCOME; ACUTE KIDNEY INJURY; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ARKANSAS; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; CRITICAL ILLNESS; MIDDLE AGED;

ACUTE KIDNEY INJURY; ANTI-BACTERIAL AGENTS; ARKANSAS; CEPHALOSPORINS; CRITICAL ILLNESS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; RETROSPECTIVE STUDIES; VANCOMYCIN;

EID: 84963784289     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1738     Document Type: Article

References (57)

1. MacDougall C, Polk RE,. Variability in rates of use of antibacterials among 130 US hospitals and risk-adjustment models for interhospital comparison. Infect Control Hosp Epidemiol 2008; 29 (3): 203-11.
2. Pakyz AL, MacDougall C, Oinonen M, Polk RE,. Trends in antibacterial use in US academic health centers: 2002 to 2006. Arch Intern Med 2008; 168 (20): 2254-60.
3. Rybak MJ, Lomaestro BM, Rotschafer JC, et al., Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49 (3): 325-7.
4. Elyasi S, Khalili H, Dashti-Khavidaki S, et al., Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 2012; 68: 1243-55.
5. Uchino S, Kellum JA, Bellomo R, et al., Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005; 294: 813-8.
6. Bentley ML, Corwin HL, Dasta J,. Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies. Crit Care Med 2010; 38 (6 Suppl): S169-74.
7. Lodise TP, Lomaestro B, Graves J, Drusano GL,. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52: 1330-6.
8. van Hal SJ, Paterson DL, Lodise TP,. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 2013; 57 (2): 734.
9. Bajaj P, Prematta M, Ghaffari G,. A sixty-five year old man with rash, fever, and generalized weakness. Allergy Asthma Proc 2011; 32 (1): e1-3.
10. Mannaerts L, Van der Wurff A, Wolfhagen F,. Interstitial nephritis attributed to treatment with piperacillin-tazobactam and with ciprofloxacin. Ned TijdschrGeneeskd 2006; 150 (14): 804-7.
11. Pratt JA, Stricherz MK, Verghese PS, Burke MJ,. Suspected piperacillin-tazobactam induced nephrotoxicity in the pediatric oncology population. Pediatr Blood Cancer 2014; 61: 366-8.
12. Liu P, Tepperman BS, Logan AG,. Acute renal failure induced by semi-synthetic penicillins. Can Fam Physician 1981; 27: 507-12.
13. Liu TJ, Lam JP,. Piperacillin-tazobactam-induced acute interstitial nephritis with possible meropenem cross-sensitivity in a patient with osteomyelitis. Am J Health Syst Pharm 2012; 13: 1109.
14. Pill MW, O'Neill CV, Chapman MM, Singh AK,. Suspected acute interstitial nephritis induced by piperacillin-tazobactam. Pharmacotherapy 1997; 1: 166-9.
15. Yamamura D, Gucalp R, Carlisle P, Cimino M, Roberts J, Rotstein C,. Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients. Antimicrob Agents Chemother 1997; 41: 1704-8.
16. Jensen JU, Hein L, Lundgren B, et al., Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial. BMJ Open 2012; 2 (2): e000635.
17. Meaney CJ, Hynicka LM, Tsoukleris MG,. Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors. Pharmacotherapy 2014; 34 (7): 653-61.
18. Moenster RP, Linneman TW, Finnegan PM, Hand S, Thomas Z, McDonald JR,. Acute renal failure associated with vancomycin and beta-lactams for the treatment of osteomyelitis in diabetics: piperacillin/tazobactam compared to cefepime. Clin Microbiol Infect 2014; 20 (6): O384-9.
19. McCormick HTN, Baggett S, Heierman T, LaFosse J, Gilbert S, Imhof K,. Comparison of acute renal injury associated with intermittent and extended infusion piperacillin/tazobactam. J Health Syst Pharm Res 2011; 1: 1-5.
20. Burgess LD, Drew RH,. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy 2014; 34 (7): 670-6.
21. Gomes DM, Smotherman C, Birch A, et al., Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. Pharmacotherapy 2014; 34 (7): 662-9.
22. Sutton JD, Mynatt RP, Kaye KS, Murray KP, Rybak MJ, Pogue JM,. Nephrotoxicity comparison of two commercially available generic vancomycin products. Antimicrob Agents Chemother 2015; 59 (9): 5470-4.
23. Patel R, Choe R, Kisgen J,. Retrospective analysis to determine the incidence of acute kidney injury in patients treated with piperacillin-tazobactam, vancomycin or the combination. In: Program and abstracts of the 2nd Annual Florida Residency Conference. Orlando, FL: Florida Society of Health-System Pharmacists Research and Education Foundation; 2013.
24. Hellwig T, Hammerquist R, Loecker B, Shields J,. Retrospective evaluation of the incidence of vancomycin and/or piperacillin-tazobactam induced acute renal failure [abstract]. Crit Care Med 2011; 12: 79.
25. Min E, Box K, Lane J, et al., Acute kidney injury in patients receiving concomitant vancomycin and piperacillin/tazobactam [abstract]. Crit Care Med 2011; 12: 200.
26. Zeiler M, Mayhall G, Lee E,. Incidence of nephrotoxicity with concomitant vancomycin and piperacillin-tazobactam versus vancomycin alone or in combination with a carbapenem, aztreonam, or levofloxacin in adult patients [abstract]. Crit Care Med 2009; 12: A415.
27. Disease K,. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012; 2: 124-38.
28. Bellomo R, Ronco C, Kellum JA, et al., Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: B204.
29. Mehta RL, Kellum JA, Shah SV, et al., Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31.
30. Austin PC,. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 2011; 46 (3): 399-424.
31. Pirracchio R, Resche-Rigon M, Chevret S,. Evaluation of the propensity score methods for estimating marginal odds ratios in case of small sample size. BMC Med Res Methodol 2010; 12 (1): 70.
32. Brookhart MA, Wyss R, Layton JB, Stürmer T,. Propensity score methods for confounding control in non-experimental research. Circulat Cardiovasc Qual Outcomes 2013; 6 (5): 604-11.
33. Cano EL, Haque NZ, Welch VL, et al., Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP database. Clin Ther 2012; 34: 149-57.
34. Hanrahan T, Whitehouse T, Lipman J, Roberts JA,. Vancomycin-associated nephrotoxicity: a meta-analysis of administration by continuous versus intermittent infusion. Int J Antimicrob Agents 2015; 46 (3): 249-53.
35. Minejima E, Choi J, Beringer P, Lou M, Tse E, Wong-Beringer A,. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob Agents Chemother 2011; 55 (7): 3278-83.
36. Sileanu FE, Murugan R, Lucko N, et al., AKI in low-risk versus high-risk patients in intensive care. Clin J Am Soc Nephrol 2015; 10 (2): 187-96.
37. Murugan R, Karajala-Subramanyam V, Lee M, et al., Acute kidney injury in nonsevere pneumonia is associated with an increased immune response and lower survival. Kidney Int 2010; 77: 527-35.
38. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL,. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49: 507-14.
39. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A,. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166: 2138-44.
40. Le Dorze M, Legrand M, Payen D, Ince C,. The role of the microcirculation in acute kidney injury. Curr Opin Crit Care 2009; 15: 503-8.
41. Kralovicová K, Spanik S, Halko J, et al., Do vancomycin serum levels predict failures of vancomycin therapy or nephrotoxicity in cancer patients? J Chemother 1997; 9: 420-6.
42. Hermsen ED, Hanson M, Sankaranarayanan J, Stoner JA, Florescu MC, Rupp ME,. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf 2010; 9: 9-14.
43. Colares VS, Oliveira RB, Abdulkader R,. Nephrotoxicity of vancomycin in patients with normal serum creatinine. Nephrol Dial Transplant 2006; 21: 3608.
44. Wan Y,. Link between initial vancomycin concentration time profile and nephrotoxicity in hospitalized patients. Clin Infect Dis 2009; 49: 507-14.
45. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH,. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007; 29 (6): 1107-15.
46. Prabaker KK, Tran TP, Pratummas T, Goetz MB, Graber CJ,. Elevated vancomycin trough is not associated with nephrotoxicity among inpatient veterans. J Hosp Med 2012; 7 (2): 91-7.
47. Jeurissen A, Sluyts I, Rutsaert R,. A higher dose of vancomycin in continuous infusion is needed in critically ill patients. Int J Antimicrob Agents 2011; 37 (1): 75-7.
48. Cohen E, Dadashev A, Drucker M, Samra Z, Rubinstein E, Garty M,. Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients. J Antimicrob Chemother 2002; 49 (1): 155-60.
49. Gupta A, Biyani M, Khaira A,. Vancomycin nephrotoxicity: myths and facts. Neth J Med 2011; 69: 379-83.
50. Nishino Y, Takemura S, Minamiyama Y, et al., Inhibition of vancomycin-induced nephrotoxicity by targeting superoxide dismutase to renal proximal tubule cells in the rat. Redox Rep 2002; 5: 317-9.
51. King DW, Smith MA,. Proliferative responses observed following vancomycin treatment in renal proximal tubule epithelial cells. Toxicol In Vitro 2004; 6: 797-803.
52. Le Moyec L, Racine S, Le Toumelin P, et al., Aminoglycoside and glycopeptide renal toxicity in intensive care patients studied by proton magnetic resonance spectroscopy of urine. Crit Care Med 2002; 6: 1242-5.
53. Baldwin DS, Levine BB, McCluskey RT, Gallo GR,. Renal failure and interstitial nephritis due to penicillin and methicillin. N Engl J Med 1968; 23: 1245-52.
54. Sakarcan A, Marcille R, Stallworth J,. Antibiotic-induced recurring interstitial nephritis. Pediatr Nephrol 2002; 1: 50-1.
55. Mac K, Chavada R, Paull S, Howlin K, Wong J,. Cefepime induced acute interstitial nephritis-a case report. BMC Nephrol 2015; 16: 15.
56. Elsayed MG, Elkomy AA, Gaballah MS, Elbadawy M,. Nephrotoxicity of cefepime: a new cephalosporin antibiotic in rats. J Pharmacol Pharmacother 2014; 5 (1): 33-8.
57. Fewell Z, Davey Smith G, Sterne JA,. The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. Am J Epidemiol 2007; 166 (6): 646-55.